$福泰制药(VRTX)$ Vertex wins a crucial FDA nod for its cystic fibrosis combo, prices at $259,000. The agency signed off on Vertex's Orkambi, which combines the investigational lumacaftor with ivacaftor, already marketed as Kalydeco. Orkambi is designed for the roughly 8,500 patients whose CF is caused by the so-called F508del mutation in their CFTR genes, making up the disease's largest population. Kalydeco, first approved in 2012, is cleared to treat CF patients with different CFTR mutations, a group totaling roughly 2,000, according to Vertex